X
[{"orgOrder":0,"company":"Cellivery","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellivery, iCP-NI 'Corona 19' Primate Treatment Efficacy Verification Begins","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Cellivery
Filters
Companies By Therapeutic Area
Details:
The new drug iCP-NI begins to verify the efficacy of treatment for the treatment of acute pneumonia and severe sepsis caused by corona19.
Lead Product(s):
iCP-NI
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 27, 2020